<?xml version='1.0' encoding='utf-8'?>
<document id="31628668"><sentence text="Dose-Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs."><entity charOffset="39-49" id="DDI-PubMed.31628668.s1.e0" text="Rifampicin" /></sentence><sentence text="To address the most appropriate endogenous biomarker for drug-drug interaction risk assessment, eight healthy subjects received an organic anion transporting polypeptide 1B (OATP1B) inhibitor (rifampicin, 150, 300, and 600 mg), and a probe drug cocktail (atorvastatin, pitavastatin, rosuvastatin, and valsartan)"><entity charOffset="193-203" id="DDI-PubMed.31628668.s2.e0" text="rifampicin" /><entity charOffset="255-267" id="DDI-PubMed.31628668.s2.e1" text="atorvastatin" /><entity charOffset="269-281" id="DDI-PubMed.31628668.s2.e2" text="pitavastatin" /><entity charOffset="283-295" id="DDI-PubMed.31628668.s2.e3" text="rosuvastatin" /><entity charOffset="301-310" id="DDI-PubMed.31628668.s2.e4" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.31628668.s2.e0" e2="DDI-PubMed.31628668.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31628668.s2.e0" e2="DDI-PubMed.31628668.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31628668.s2.e0" e2="DDI-PubMed.31628668.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31628668.s2.e0" e2="DDI-PubMed.31628668.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31628668.s2.e0" e2="DDI-PubMed.31628668.s2.e4" /><pair ddi="false" e1="DDI-PubMed.31628668.s2.e1" e2="DDI-PubMed.31628668.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31628668.s2.e1" e2="DDI-PubMed.31628668.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31628668.s2.e1" e2="DDI-PubMed.31628668.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31628668.s2.e1" e2="DDI-PubMed.31628668.s2.e4" /><pair ddi="false" e1="DDI-PubMed.31628668.s2.e2" e2="DDI-PubMed.31628668.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31628668.s2.e2" e2="DDI-PubMed.31628668.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31628668.s2.e2" e2="DDI-PubMed.31628668.s2.e4" /><pair ddi="false" e1="DDI-PubMed.31628668.s2.e3" e2="DDI-PubMed.31628668.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31628668.s2.e3" e2="DDI-PubMed.31628668.s2.e4" /></sentence><sentence text=" In addition to coproporphyrin I, a widely studied OATP1B biomarker, we identified at least 4 out of 28 compounds (direct bilirubin, glycochenodeoxycholate-3-glucuronide, glycochenodeoxycholate-3-sulfate, and hexadecanedioate) that presented good sensitivity and dynamic range in terms of the rifampicin dose-dependent change in area under the plasma concentration-time curve ratio (AUCR)"><entity charOffset="122-131" id="DDI-PubMed.31628668.s3.e0" text="bilirubin" /><entity charOffset="133-169" id="DDI-PubMed.31628668.s3.e1" text="glycochenodeoxycholate-3-glucuronide" /><entity charOffset="171-203" id="DDI-PubMed.31628668.s3.e2" text="glycochenodeoxycholate-3-sulfate" /><entity charOffset="209-225" id="DDI-PubMed.31628668.s3.e3" text="hexadecanedioate" /><entity charOffset="293-303" id="DDI-PubMed.31628668.s3.e4" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.31628668.s3.e0" e2="DDI-PubMed.31628668.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31628668.s3.e0" e2="DDI-PubMed.31628668.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31628668.s3.e0" e2="DDI-PubMed.31628668.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31628668.s3.e0" e2="DDI-PubMed.31628668.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31628668.s3.e0" e2="DDI-PubMed.31628668.s3.e4" /><pair ddi="false" e1="DDI-PubMed.31628668.s3.e1" e2="DDI-PubMed.31628668.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31628668.s3.e1" e2="DDI-PubMed.31628668.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31628668.s3.e1" e2="DDI-PubMed.31628668.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31628668.s3.e1" e2="DDI-PubMed.31628668.s3.e4" /><pair ddi="false" e1="DDI-PubMed.31628668.s3.e2" e2="DDI-PubMed.31628668.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31628668.s3.e2" e2="DDI-PubMed.31628668.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31628668.s3.e2" e2="DDI-PubMed.31628668.s3.e4" /><pair ddi="false" e1="DDI-PubMed.31628668.s3.e3" e2="DDI-PubMed.31628668.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31628668.s3.e3" e2="DDI-PubMed.31628668.s3.e4" /></sentence><sentence text=" Their suitability as OATP1B biomarkers was also supported by the good correlation of AUC0-24h between the endogenous compounds and the probe drugs, and by nonlinear regression analysis (AUCR-1 vs" /><sentence text=" rifampicin plasma Cmax (maximum total concentration in plasma)) to yield an estimate of the inhibition constant of rifampicin"><entity charOffset="1-11" id="DDI-PubMed.31628668.s5.e0" text="rifampicin" /><entity charOffset="116-126" id="DDI-PubMed.31628668.s5.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.31628668.s5.e0" e2="DDI-PubMed.31628668.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31628668.s5.e0" e2="DDI-PubMed.31628668.s5.e1" /></sentence><sentence text=" These endogenous substrates can complement existing OATP1B-mediated drug-drug interaction risk assessment approaches based on agency guidelines in early clinical trials" /><sentence text="" /></document>